competitors, page-7

ST;
My point was not that this had failed but that it is competing in a different market segment - the warfarin segment. I agree though that the Arixtra market may well stabilise - more likely at around $450-500 million with the approval of the PE indication.

The last sales figures for Arixtra that I saw were for the first quarter '07. I would anticipate a 12-15% uplift on those figures which would give an annualised sales increment of 50-70%. I would anticipate a bigger rise once PE is approved in the US. I guess we will know soon but the trajectory is up.